| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hsiang-Chun Lai, Hung-Jen Lin, Ying-Hsiu Shih, Jen-Wei Chou, Kuan-Wen Lin, Long-Bin Jeng and Sheng-Teng Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Technology of Taiwan |
NSTC111-2320-B-039-025 |
| China Medical University Hospital |
DMR-111-013 |
| China Medical University Hospital |
DMR-111-195 |
|
| Corresponding Author |
Sheng-Teng Huang, MD, PhD, Doctor, Department of Chinese Medicine, China Medical University Hospital, No. 2 Yude Road, North District, Taichung 40447, Taiwan. sheng.teng@yahoo.com |
| Key Words |
LipoCol Forte capsules; Hyperlipidemia; Liver cancer; Hepatocellular carcinoma; Retrospective cohort study; Taiwan National Health Insurance Research Database |
| Core Tip |
LipoCol Forte capsules (LFC), a red yeast rice product, have lipid-lowering effects and good safety reports. Lipid-lowering therapies such as statins can lower the risk of liver cancer, but may also cause liver damage. We evaluated whether LFC lowers the risk of liver cancer in adults in this propensity score-matched, nationwide, population-based cohort study. The LFC cohort had a 9% lower incidence of liver cancer compared with controls; this lower risk was dose-dependent and time-dependent, with a 0.64-fold lower risk found in those using LFC for more than 84 drug days. The lowest incidence of liver cancer occurred in LFC users followed-up for more than 6 years. |
| Publish Date |
2023-05-12 09:13 |
| Citation |
Lai HC, Lin HJ, Shih YH, Chou JW, Lin KW, Jeng LB, Huang ST. LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study. World J Gastrointest Oncol 2023; 15(5): 828-842 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i5/828.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i5.828 |
